Atlantic Canada’s Value Proposition Re$earch Money Conference November, 2007 Halifax, Nova Scotia

Atlantic Canada’s Value Proposition Context to remarks Understanding BioVectra Inc. and Diagnostic Chemicals Limited Our in-house research capabilities and focus Our collaborations with Atlantic Canada researchers and organizations Our collaborations with Pharmaceutical and Diagnostic companies

Founded in 1970 by Dr. Regis Duffy Privately held and controlled DCL employs over 240 people in 3 countries Four manufacturing facilities plus administration headquarters in Canada; sales and distribution offices in the United States and Mexico Develops, manufactures and markets products worldwide DCL and BioVectra

Prince Edward Island, Canada Manufacturing / Packaging Administration Research and Development Quality Control Regulatory Affairs Technical Services Oxford, Connecticut Customer Services and Warehousing Field Sales and Technical Services Mexico City, Mexico Customer Services and Warehousing Sales and Field Technical Services DCL and BioVectra

Corporate Overview Revenue

DCL and BioVectra Actual and Projected Revenue

Develops, manufactures and markets worldwide: Chemistry reagents for human and veterinary diagnostics Specialty / Niche chemistry reagents for human and veterinary diagnostics Immunochromatographic point-of-care assays Laboratory consumable manufacturing on a contract basis Diagnostics Provides services in: Contract Sales and Distribution Custom product formulations/manufacturing Lyophilization, dry and liquid blending Full kitting including dispensing and labeling Applications development / FDA filing

Diagnostics Strategy R & D: External Collaboration Diagnostic companies with problem chemistries Universities with technologies in clinical chemistry Small firms or individuals with unique chemistries Internal Activities focus on product development

Diagnostics – keys to success Focus on Manufacturing Excellence Unique Products Customer Service Human capital A very good fit with Genzyme Corporation

BioVectra is a cGMP manufacturer of APIs and advanced intermediates Fermentation Bioextractions and purifications PEG reagents & PEGylation services Specialty biochemicals and enzymes Creating partnerships with others utilizing our applied technologies to improve or enhance new and existing products

BioVectra R & D: External collaboration Pharma and Biotech companies with unique problems Universities NRC-INH Drug discovery companies

BioVectra R & D: Internal Activities PEGs ( a product used as part of the drug, to extend stability and improve performance ) Taxanes – to gain an advantage in generic introduction of a semi-synthetic version of a major oncology drug New Drug Development program – a structure to invest in development of selected candidates

BioVectra Keys to Success: Focus on Manufacturing Excellence Unique Products Customer Service Human Capital

Atlantic Canada’s Value Proposition North American strategic location Good cost base for technical activities and manufacturing Quality of life for employees is appreciated and creates loyalty Low bureaucracy, ‘can-do’ attitude Excellent public support climate Institutional support - NRC, AVC, Universities

Atlantic Canada Value Proposition Strong support and collaborative system in place; example - PEI BioAlliance Canadian Business 2007 ranked Charlottetown as the 2nd best place to do business in Canada Provincial Tax Incentives – Corporate tax, HR Recruitment support ACOA Atlantic Innovation Fund (AIF) reduces product development risks

Some challenges Experience base is limited among available labor Challenging to retain young mobile talent Must overcome perceptions of remote location – access is an issue Removed from financial sources typically used by competition

Atlantic Canada’s Value Proposition Atlantic Canada can contribute to the national science and business goals Think about it; Strong university environment Well educated work force Strong work ethic Entrepreneurial spirit Local government willing to support economic innovation

Atlantic Canada’s Value Proposition Some comments: Message to Governments – “Atlantic Canada is stepping up” as a serious business contender in the science area ACOA- AIF is an important tool for technology transfer and commercialization Maintain and improve competitive tax incentives for science based businesses Develop policies and incentives to attract world-class researchers and highly qualified personnel Invest more in infrastructure and less on strategic forms

Atlantic Canada’s Value Proposition This sector is an opportunity for Atlantic Canada to shine – We are committed to making this happen